Stockscreener 앱 받기
5.68
1.43%
0.08
전일 마감가:
$5.60
열려 있는:
$5.66
하루 거래량:
473.16K
Relative Volume:
0.62
시가총액:
$311.82M
수익:
$124.00K
순이익/손실:
$-49.99M
주가수익비율:
-3.3609
EPS:
-1.69
순현금흐름:
$-31.03M
1주 성능:
-2.57%
1개월 성능:
-7.34%
6개월 성능:
-11.25%
1년 성능:
-35.60%
1일 변동 폭
$5.61
$5.82
1주일 범위
$5.3994
$5.9891
52주 변동 폭
$4.25
$13.68
Candel Therapeutics Inc Stock (CADL) Company Profile
명칭
Candel Therapeutics Inc
전화
617-916-5445
주소
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
5.68 | 307.43M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-28 | 개시 | Stephens | Overweight |
| 2025-09-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-06-30 | 재개 | H.C. Wainwright | Buy |
| 2025-02-20 | 개시 | Citigroup | Buy |
| 2025-02-19 | 개시 | Canaccord Genuity | Buy |
| 2025-02-07 | 개시 | BofA Securities | Buy |
| 2022-12-02 | 개시 | H.C. Wainwright | Buy |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-08-23 | 개시 | Credit Suisse | Outperform |
| 2021-08-23 | 개시 | Jefferies | Buy |
| 2021-08-23 | 개시 | UBS | Buy |
모두보기
Candel Therapeutics Inc 주식(CADL)의 최신 뉴스
Is Candel Therapeutics Inc. stock a safe haven assetJuly 2025 Earnings & Weekly High Return Stock Forecasts - mfd.ru
Can Candel Therapeutics Inc. be the next market leaderWall Street Watch & Momentum Based Trading Signals - mfd.ru
What is the fair value of Candel Therapeutics Inc. stock now2025 Fundamental Recap & Low Risk Entry Point Guides - mfd.ru
Candel Therapeutics (CADL) Stock Analysis: A Biotech With A 236% Upside Potential - DirectorsTalk Interviews
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit - The Manila Times
Glioblastoma biomarkers, imaging and trials: Candel to outline data in Boston - Stock Titan
Candel Therapeutics to highlight glioblastoma immunotherapy data at Boston summit - Proactive financial news
Aug Sentiment: What is the fair value of Candel Therapeutics Inc. stock nowJuly 2025 Reactions & Weekly Top Stock Performers List - mfd.ru
Precision Trading with Candel Therapeutics Inc. (CADL) Risk Zones - Stock Traders Daily
Ideas Watch: Will Candel Therapeutics Inc face regulatory challengesQuarterly Portfolio Report & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Candel Therapeutics Advances Gene-Based Prostate Cancer Trial With New Biomarker Update - TipRanks
Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - The Malaysian Reserve
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Candel Therapeutics announces inducement grants under Nasdaq listing rule - marketscreener.com
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule - TradingView
New Candel hire receives 6,600 stock options as joining inducement - Stock Titan
Is Candel Therapeutics Inc. on track to beat earningsJuly 2025 Highlights & Verified Swing Trading Watchlist - mfd.ru
Candel Therapeutics, Inc. (CADL) Stock Analysis: Exploring a Potential 224% Upside in Biotech Innovation - DirectorsTalk Interviews
Technical Reactions to CADL Trends in Macro Strategies - Stock Traders Daily
Candel Therapeutics, Inc. (NASDAQ:CADL) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Candel Therapeutics, Inc. (NASDAQ:CADL) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
What is the earnings history of Candel Therapeutics Inc.Insider Selling & Precise Trade Entry Recommendations - mfd.ru
Oncolytic Virotherapy Market - GlobeNewswire Inc.
Candel Therapeutics, Inc. (CADL) Stock Analysis: A Biotech With 195.63% Potential Upside - DirectorsTalk Interviews
Candel Therapeutics (NASDAQ:CADL) Stock Rating Lowered by Zacks Research - MarketBeat
New Strong Sell Stocks for January 20th - sharewise.com
Is Candel Therapeutics Inc. stock affected by interest rate hikesQuarterly Growth Report & Growth Focused Investment Plans - bollywoodhelpline.com
Trading the Move, Not the Narrative: (CADL) Edition - Stock Traders Daily
Breakeven On The Horizon For Candel Therapeutics, Inc. (NASDAQ:CADL) - simplywall.st
Aug Highlights: Will Xometry Inc stock recover after earningsPortfolio Risk Report & Pattern Based Trade Signal System - baoquankhu1.vn
Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term - Yahoo Finance
Sectors Review: Will Candel Therapeutics Inc stock maintain momentum in 2025Earnings Trend Report & Consistent Profit Alerts - Bộ Nội Vụ
Valuation Update: Will Candel Therapeutics Inc. stock outperform tech sector in 2025IPO Watch & Consistent Profit Trade Alerts - Улправда
Can Candel Therapeutics Inc. stock attract ESG capital inflows2025 Momentum Check & Consistent Return Strategy Ideas - Улправда
Aug Volume: Will Candel Therapeutics Inc. stock outperform tech sector in 20252025 Analyst Calls & Free Weekly Chart Analysis and Trade Guides - Улправда
Can Candel Therapeutics Inc. stock sustain free cash flow growth2025 Valuation Update & Trade Opportunity Analysis - Улправда
Will Candel Therapeutics Inc. stock outperform tech sector in 2025IPO Watch & Consistent Profit Trade Alerts - Улправда
Analysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Stereotaxis (STXS) - The Globe and Mail
(CADL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Understanding the Setup: (CADL) and Scalable Risk - Stock Traders Daily
Candel Therapeutics, Inc.(NasdaqGM: CADL) added to NASDAQ Biotechnology Index - marketscreener.com
Can Candel Therapeutics Inc. stock surprise with earnings upside2025 Momentum Check & Risk Adjusted Buy/Sell Alerts - Улправда
Candel Therapeutics Earnings Notes - Trefis
Why Candel Therapeutics Inc. stock is rated strong buyOil Prices & Stepwise Swing Trade Plans - Улправда
Will Candel Therapeutics Inc. stock outperform Dow Jones index2025 AllTime Highs & Long-Term Capital Growth Ideas - DonanımHaber
Will Candel Therapeutics Inc. stock maintain growth storyStop Loss & AI Powered Buy and Sell Recommendations - Улправда
Bear Alert: Why Candel Therapeutics Inc. stock is rated strong buyWeekly Gains Summary & Weekly Breakout Watchlists - Улправда
How (CADL) Movements Inform Risk Allocation Models - Stock Traders Daily
B of A Securities Downgrades Candel Therapeutics (CADL) - MSN
Candel Therapeutics, Inc. $CADL is Acorn Capital Advisors LLC's 5th Largest Position - MarketBeat
Candel Therapeutics Inc (CADL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Candel Therapeutics Inc 주식 (CADL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Nichols William Garrett | Chief Medical Officer |
Jul 28 '25 |
Sale |
6.98 |
937 |
6,540 |
52,493 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Option Exercise |
1.29 |
781 |
1,007 |
53,274 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Sale |
5.04 |
781 |
3,936 |
52,493 |
1.12%
0.87%
자본화:
|
볼륨(24시간):